
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
In adults being treated for
This is one of 7 recommendations on the detection and management of white coat and masked hypertension made in the landmark
In this brief slide show for primary care practitioners, we summarize all 7 recommendations as well as the evidence in support of each.






